GLP-1 Receptor Agonists Cut Atrial Fibrillation Risk by 41% in Non-Dialysis CKD Patients

Patients with chronic kidney disease (CKD) face a heightened risk of cardiovascular complications, including atrial fibrillation (AF), a common and serious arrhythmia. While GLP-1 receptor agonists (GLP-1 RAs) are known to improve cardiorenal outcomes in CKD patients with obesity or type 2 diabetes, their impact on AF risk, particularly in CKD patients without these comorbidities, has remained unclear. This study addresses this critical gap, exploring the potential of GLP-1 RAs to offer broader cardiovascular protection beyond their established metabolic benefits.

Researchers utilized the TriNetX US Collaborative Network to identify 37,768 patients with CKD but no prior AF or kidney failure. They created two 1:1 propensity-score-matched cohorts: one exposed to GLP-1 RA use (index event: first use) and a non-user control group (pseudo-index event: outpatient visit after CKD diagnosis). Both cohorts were followed for up to 3 years for incident AF (primary outcome) and secondary outcomes including AF-related interventions (ablation, cardioversion, etc.), heart failure exacerbation, and antiarrhythmic therapy use. Survival analyses were performed to assess associations.